Kristen Snow
Family · Cranston, RINPI 1568827517
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,219 of the $6,364 with a category attached, or 82.0%. It is spread thinly across 29 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,406, 4.3 times the $559 reported in 2021. Among family clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$1K
- Novo Nordisk$527
- Pfizer$470
- AstraZeneca$441
- Teva Pharmaceuticals USA, Inc.$400
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$1,10017%
- Food & beverage$5,21982%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $1,460 |
| AbbVie | 61 | $1,212 |
| Novo Nordisk | 29 | $527 |
| Pfizer | 23 | $470 |
| AstraZeneca | 22 | $441 |
| Teva Pharmaceuticals USA, Inc. | 24 | $400 |
| Exact Sciences | 14 | $293 |
| Amgen | 18 | $263 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| Merck | 6 | $127 |
| Cranial Technologies, Inc | 6 | $113 |
| Corium, LLC | 5 | $102 |
| Mayne Pharma Commercial LLC | 7 | $95 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| GSK | 3 | $58 |
| Lundbeck LLC | 3 | $57 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Collegium Pharmaceutical, Inc. | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Lucid Diagnostics Inc. | 2 | $35 |
| Bayer | 2 | $30 |
| Exeltis, USA Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$1,100
How this compares
$6,364 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 58 | $62,647 |
| OzempicSemaglutide | 45 | $41,539 |
| EliquisApixaban | 14 | $10,229 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,106 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,305 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,244 |
| LinzessLinaclotide | 14 | $7,103 |
| Naloxone Hcl | 30 | $1,684 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,584 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,235 |
| Potassium Chloride | 25 | $1,110 |
| Omeprazole | 83 | $865 |
| Atorvastatin Calcium | 80 | $752 |
| Gabapentin | 32 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,460 | $62,64758 claims |
| Novo NordiskOzempic | $527 | $41,53945 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $58 | $15,41133 claims |
| PfizerEliquis | $470 | $10,22914 claims |
| AstraZenecaBreztri Aerosphere | $441 | $7,24412 claims |
| AbbVieLinzess | $1,212 | $7,10314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.
Other family in Cranston
- Gabriel SimoesCranston$2K
- Jackeline RamosCranston$2K
- Carol RobinsonWarwick$82K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Alicia VatterWarwick$15K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
- Sharon BensonNorth Smithfield$12K
- Michelle Blade MelloWest Warwick$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.